Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)
South Korea flag South Korea · Delayed Price · Currency is KRW
7,840.00
+40.00 (0.51%)
Apr 10, 2026, 3:30 PM KST

Vaxcell-Bio Therapeutics Revenue

In the year 2024, Vaxcell-Bio Therapeutics had annual revenue of 1.90B KRW with 13,737.28% growth. Vaxcell-Bio Therapeutics had revenue of 921.53M in the quarter ending December 31, 2024, with 6,615.06% growth.

Revenue
1.90B
Revenue Growth
+13,737.28%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
181.41B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20241.90B1.89B13,737.28%
Dec 31, 202313.72M--
Dec 31, 2022---
Dec 31, 2021---
Dec 31, 2020---
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
EASY BIO,Inc.476.94B
Bioneer330.11B
Macrogen195.27B
JETEMA,76.90B
HLB Therapeutics69.56B
Amicogen41.98B
CG Invites27.39B
Genexine5.81B
Revenue Rankings